Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current research on influenza and other respiratory viruses: II international symposium.

Literature DB >> 10854663

Current research on influenza and other respiratory viruses: II international symposium.

F M Munoz¹, G J Galasso, J M Gwaltney, F G Hayden, B Murphy, R Webster, P Wright, R B Couch.

Abstract

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：
Antiviral Agents

Year: 2000 PMID： 10854663 PMCID： PMC7134186 DOI： 10.1016/s0166-3542(00)00092-9

Source DB: PubMed Journal: Antiviral Res ISSN： 0166-3542 Impact factor: 5.970

× No keyword cloud information.

46 in total

1. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies.

Authors: C A Siegrist; H Plotnicky-Gilquin; M Córdova; M Berney; J Y Bonnefoy; T N Nguyen; P H Lambert; U F Power
Journal: J Infect Dis Date: 1999-06 Impact factor: 5.226

2. The impact of influenza epidemics on mortality: introducing a severity index.

Authors: L Simonsen; M J Clarke; G D Williamson; D F Stroup; N H Arden; L B Schonberger
Journal: Am J Public Health Date: 1997-12 Impact factor: 9.308

3. Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors: R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal: J Infect Dis Date: 1974-04 Impact factor: 5.226

4. Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction.

Authors: K O Schowengerdt; J Ni; S W Denfield; R J Gajarski; B Radovancevic; H O Frazier; G J Demmler; D Kearney; J T Bricker; J A Towbin
Journal: J Heart Lung Transplant Date: 1996-02 Impact factor: 10.247

5. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach.

Authors: J Talon; M Salvatore; R E O'Neill; Y Nakaya; H Zheng; T Muster; A García-Sastre; P Palese
Journal: Proc Natl Acad Sci U S A Date: 2000-04-11 Impact factor: 11.205

6. Influenza virus resistance to neuraminidase inhibitors.

Authors: D B Mendel; R W Sidwell
Journal: Drug Resist Updat Date: 1998 Impact factor: 18.500

7. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children.

Authors: R A Karron; P F Wright; F K Newman; M Makhene; J Thompson; R Samorodin; M H Wilson; E L Anderson; M L Clements; B R Murphy
Journal: J Infect Dis Date: 1995-12 Impact factor: 5.226

8. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A: a comparison of 2 protocols.

Authors: P J Drinka; S Gravenstein; M Schilling; P Krause; B A Miller; P Shult
Journal: Arch Intern Med Date: 1998-10-26

9. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children.

Authors: J C King; A R Burke; J D Clemens; P Nair; J J Farley; P E Vink; S R Batlas; M Rao; J P Johnson
Journal: Pediatr Infect Dis J Date: 1993-09 Impact factor: 2.129

Review 10. Influenza virus neuraminidase: structure, antibodies, and inhibitors.

Authors: P M Colman
Journal: Protein Sci Date: 1994-10 Impact factor: 6.725

10 in total

Review 1. Current research on respiratory viral infections: Third International Symposium.

Authors: A C Schmidt; R B Couch; G J Galasso; F G Hayden; J Mills; B R Murphy; R M Chanock
Journal: Antiviral Res Date: 2001-06 Impact factor: 5.970

2. The cellular RNA helicase UAP56 is required for prevention of double-stranded RNA formation during influenza A virus infection.

Authors: Christian Wisskirchen; Thomas H Ludersdorfer; Dominik A Müller; Eva Moritz; Jovan Pavlovic
Journal: J Virol Date: 2011-06-15 Impact factor: 5.103

Current research on influenza and other respiratory viruses: II international symposium.

1. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies.

2. The impact of influenza epidemics on mortality: introducing a severity index.

3. Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

4. Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction.

5. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach.

6. Influenza virus resistance to neuraminidase inhibitors.

7. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children.

8. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A: a comparison of 2 protocols.

9. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children.

Review 10. Influenza virus neuraminidase: structure, antibodies, and inhibitors.

Review 1. Current research on respiratory viral infections: Third International Symposium.

2. The cellular RNA helicase UAP56 is required for prevention of double-stranded RNA formation during influenza A virus infection.

Review 3. Current research on respiratory viral infections: Fourth International Symposium.

4. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus.

5. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.

Review 6. Antivirals for influenza: what is their role in the older patient?

7. Current research on respiratory viral infections: Fifth International Symposium.

8. Respiratory viruses associated with patients older than 50 years presenting with ILI in Senegal, 2009 to 2011.

9. Antiviral agents against respiratory viruses.

Review 10. Treatment of respiratory virus infections.